Logo image
Repurposing Renin–Angiotensin System Drugs for the Treatment of Audiovestibular Disorders
Journal article   Open access   Peer reviewed

Repurposing Renin–Angiotensin System Drugs for the Treatment of Audiovestibular Disorders

Grant Podhajsky, Kiran S. Marla, Alec P. Marticoff, Kenny Nguyen, Tanner Kempton, Sepehr Salehpour, Caden Duffy and Douglas M. Bennion
Journal of clinical medicine, Vol.15(2), 743
01/16/2026
DOI: 10.3390/jcm15020743
PMID: 41598680
url
https://doi.org/10.3390/jcm15020743View
Published (Version of record) Open Access

Abstract

Audiovestibular disorders arising from the inner ear (e.g., hearing loss, tinnitus, vertigo) are widely prevalent in the United States. Yet, medical treatments targeting the underlying pathology of these disorders remain scarce. The practice of repurposing FDA-approved drugs for new therapeutic indications has become increasingly common, offering a lower risk route to treatment development with fewer barriers to implementation, as safety profiles are already established. The renin–angiotensin system (RAS) is well known for its role in blood pressure and fluid balance, and its overactivation induces acute and chronic inflammation and oxidative stress. This review discusses existing evidence and proposed otoprotective mechanisms of RAS inhibition, specifically using angiotensin II type 1 receptor blockers (ARBs), which support the repurposing of these medications as novel treatments to affect the inner ear pathologies that underlay hearing loss, tinnitus, and vertigo.
renin-angiotensin system angiotensin II angiotensin II type 1 receptor sensorineural hearing loss tinnitus vertigo oxidative stress inflammation blood-labyrinth barrier

Details

Metrics

10 Record Views
Logo image